Loading patent…
AssigneeOno Pharmaceutical Co., Ltd.
InventorsShiro SHIBAYAMA, Takuya SHIMBO, Tomoya TEZUKA, Mark THROSBY, Cornelis Adriaan de KRUIF, Pieter Fokko van LOO, Rinse KLOOSTER
Estimating the term…
A bispecific antibody which is capable of specifically binding to PD-1 and CD3 is disclosed. The bispecific antibody is suitable for preventing, suppressing symptom progression or recurrence of, and/or treating autoimmune diseases. Also disclosed is a formulation which can reduce occurrence of adverse infusion reactions or adverse reaction called cytokine release syndrome. The bispecific antibody has the feature to allow interaction between PD-1 and PD-L1 as its ligand, contributes enhancement or duration of its effects.
A bispecific antibody specifically binding to PD-1 and CD3 or an antibody fragment thereof, comprising a first arm specifically binding to PD-1 and a second arm specifically binding to CD3,
A bispecific antibody specifically binding to PD-1 and CD3 or antibody fragment thereof, having a first arm specifically binding to PD-1 and a second arm specifically binding to CD3, wherein
A bispecific antibody specifically binding to PD-1 and CD3 or antibody fragment thereof, having a first arm specifically binding to PD-1 and a second arm specifically binding to CD3, wherein the first arm specifically binding to PD-1 cross-competes for (1) the binding to PD-1 with a first arm specifically binding to PD-1 having a VH comprising the amino acid sequence set forth in any one selected from SEQ ID NO:
A bispecific antibody specifically binding to PD-1 and CD3 or antibody fragment thereof, having a first arm specifically binding to PD-1 and a second arm specifically binding to CD3, wherein the binding to PD-1 with the first arm specifically binding to PD-1 is cross-competed (1) by a first arm specifically binding to PD-1 having a VH comprising the amino acid sequence set forth in any one selected from SEQ ID NO:
Dependencies are inferred from the claim text.